Organon & Co.

This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy, Medicare drug pricing, and international trade agreements directly and significantly impact Organon's profitability and market access.

This committee directly allocates discretionary federal spending. Its subcommittees determine funding for regulatory bodies (FDA), research (NIH), and major healthcare programs (Medicare/Medicaid), critically impacting Organon's regulatory environment and market demand.

This is a primary regulatory committee for Organon, with direct oversight of the FDA (drug approval) and NIH (research funding), as well as labor laws that impact manufacturing operations.

This committee oversees intellectual property (patents) and antitrust laws, both critical to the pharmaceutical industry. IP protection is fundamental to drug development, and antitrust actions impact M&A strategies for companies like Organon.

The committee oversees the Department of Veterans Affairs, which is a major purchaser and healthcare provider. Its funding decisions directly impact government healthcare contractors and demand for pharmaceutical products like those manufactured by Organon.